Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe honest answer is that Ozempic and Mounjaro are not comparable on price for weight loss, because Ozempic is licensed in the UK for type 2 diabetes, not weight management. If you're looking to lose weight with a prescription medicine, the relevant comparison is between Mounjaro and Wegovy. That said, the cost question matters, and this page walks through exactly what UK private treatment actually costs and what drives those numbers.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear most weeks is some version of: "Can I just get Ozempic? It seems cheaper." The short answer is no, and the reason matters. Ozempic contains semaglutide and is licensed by the MHRA for type 2 diabetes, not weight management. The Mounjaro vs Ozempic price picture looks straightforward on the surface, but it obscures a fundamental licensing difference: prescribing Ozempic to someone without diabetes, for the purpose of losing weight, falls outside its UK licence. Any clinic offering it to you on that basis should be a red flag, not a bargain.
The weight-loss medicines licensed in the UK are Mounjaro (tirzepatide, made by Eli Lilly) and Wegovy (semaglutide, made by Novo Nordisk). Both are prescription-only medicines requiring a clinical assessment before a prescriber can issue them. If you're weighing up costs, those are the two products to compare, and our guide on what's cheaper, Wegovy or Mounjaro, covers the full picture across doses and providers.
Wegovy and Ozempic contain the same active ingredient, but at different doses and under different licences. Using Ozempic as a weight-loss shortcut isn't cheaper — it's a different product being used off-label, with all the clinical and supply-chain risks that brings. The NHS medicines page on tirzepatide and the equivalent semaglutide page set out clearly what each medicine is licensed to treat.
Private Mounjaro pricing in the UK shifted significantly from September 2025, when Eli Lilly raised its list price. The highest dose's list price moved from around £122 to around £330 per four-week pen. Typical private prices across providers have since ranged roughly £149 to £375 per month depending on the dose and the clinic, as widely reported at the time of the price change. Those figures are hedged here for good reason: they vary, and they move.
More importantly, headline prices often represent just the medicine. A lower number from one provider might exclude the consultation fee, the prescription charge, delivery, and any follow-up support. When you add those back, the gap between providers narrows considerably. If you've been wondering whether Ozempic actually works out cheaper than Mounjaro, the answer involves more than the list price, and we break it down in full. The smarter question is not which number looks smallest, but what that number actually buys you.
At nume, one price covers the consultation, the prescription, the medicine, next-working-day delivery and aftercare access across the week. We don't charge separately for any of those. We're not the cheapest provider you'll find, that's a deliberate choice, not an oversight. Our approach is built around clinical rigour and a supply chain we can stand behind, and that costs something.
For a GLP-1 medicine like Mounjaro, the cheapest listing often answers the wrong question. Prescription-only medicines require clinical oversight, genuine supply chains and a registered pharmacy behind them. The MHRA has warned publicly about counterfeit weight-loss pens sold via social media and unverified websites, fake pens have contained wrong or dangerous substances, and around 20 million doses of illegally traded weight-loss medicines, worth roughly £45 million, were seized in 2025 alone. Prices far below the market range should prompt scepticism, not a click to buy.
You can verify any online pharmacy on the GPhC register. nume's pharmacy registration number is 9012878. Any seller offering these medicines without a valid prescription, or without a visible clinical assessment process, is operating outside the law and outside any safety net. The MHRA's Yellow Card scheme lets you report suspect sellers directly.
For more on how Mounjaro and Wegovy compare across both cost and clinical evidence, the Wegovy vs Mounjaro overview covers both side by side. If you want to dig into the pricing detail before your consultation, our breakdown of Mounjaro vs Ozempic cost explains the numbers clearly, and if you'd like a straightforward answer to whether Mounjaro or Wegovy is cheaper, we cover that in full too. If you'd like to understand your own eligibility, speaking to our prescribers starts with a free consultation, no commitment, reviewed the same day by a real clinician.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.